Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

NCT07234019 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Immune Thrombocytopenia
Treatment

Interventions

DRUG: Daratumumab（Anti-CD38 Monoclonal Antibody）
DRUG: Rituximab

Sponsor

Institute of Hematology & Blood Diseases Hospital, China